Imunon Receives Nasdaq Non-Compliance Notice

Imunon ( (IMNN) ) just unveiled an announcement.

On May 19, 2025, Imunon, Inc. received a notice from Nasdaq indicating non-compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. The company has until July 3, 2025, to submit a compliance plan, with the potential for an extension of up to 180 days if accepted. Failure to comply could lead to delisting, but Imunon is evaluating options to regain compliance.

The most recent analyst rating on (IMNN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Imunon stock, see the IMNN Stock Forecast page.

Spark’s Take on IMNN Stock

According to Spark, TipRanks’ AI Analyst, IMNN is a Neutral.

Imunon’s financial instability, characterized by negative revenue and cash flow metrics, significantly impacts its overall stock score. Technical indicators suggest caution, with bearish trends and lack of momentum. Though the recent earnings call highlights promising clinical progress, concerns about cash runway and funding remain. Valuation metrics further reflect the stock’s risky profile, with a negative P/E ratio and no dividend yield.

To see Spark’s full report on IMNN stock, click here.

More about Imunon

Average Trading Volume: 209,173

Technical Sentiment Signal: Sell

Current Market Cap: $6.87M

For a thorough assessment of IMNN stock, go to TipRanks’ Stock Analysis page.